2020 ASCO Virtual Direct™ Highlights
Playback speed
10 seconds
2020 ASCO Update on FDA Approved Selpercatinib in RET-Driven Thyroid Cancers: What Are the Benefits and AE? Is There Cross-Resistance with Selpercatinib and Pralsetinib?
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Jochen Lorch
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Jochen Lorch
23 views
September 17, 2020
Comments 0
Login to view comments.
Click here to Login
Head&Neck
